ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Iron-Hijacking Trojan Horse Nanoplatform Combats Implant-Associated Biofilm Infections Through Immuno-Fibrotic Remodeling.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Implant-associated biofilm infections persist due to a vicious cycle of biofilm resilience and fibrosis-driven immune exclusion. To break this cycle, we engineered a photothermal nanoplatform (CHPB@H) consisting of curcumin-loaded hollow Prussian blue (CHPB) nanoparticles embedded in an injectable thermosensitive chitosan hydrogel for near-infrared (NIR)-triggered local delivery. Upon NIR irradiation, the platform releases iron ions and curcumin that self-assemble into Fe-curcumin (Fe-Cur) complexes. These complexes act as a molecular "Trojan horse" that hijacks bacterial iron-acquisition pathways to induce ferroptosis. Concurrently, CHPB scavenges reactive oxygen species (ROS) via its intrinsic nanozyme activity and suppresses oxidative stress-driven fibroblast activation, thereby dismantling the fibrotic barrier that excludes immune effector cells. This dual action eliminates biofilms and restores immune cell infiltration into the infection site. In preclinical animal models, the therapy clears established implant infections, remodels the immune-fibrotic microenvironment, and promotes tissue regeneration. This work establishes a "clear-and-remodel" paradigm that integrates active targeted ferroptosis (via iron hijacking) with immuno-fibrotic remodeling, offering a translatable strategy for complex implant-associated biofilm infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.